What does this research mean for the field?

Rezatapopt demonstrates antitumor activity across multiple tumor types in patients with TP53 Y220C mutations. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the safety and initial effectiveness of rezatapopt in tumors with TP53 mutations.

February 28, 2026

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Key Points

To evaluate the safety and initial effectiveness of rezatapopt in tumors with TP53 mutations.
Phase 1 design
Administered to heavily pretreated patients
Monitored for adverse events and antitumor activity
Common adverse events included nausea and vomiting
Antitumor activity observed in multiple tumor types
Proof of concept for p53 reactivation established

Abstract

In this phase 1 study involving heavily pretreated patients, the most common adverse events associated with rezatapopt were nausea and vomiting. Antitumor activity occurred across multiple tumor types, providing proof of concept for p53 reactivation. (Funded by PMV Pharmaceuticals; PYNNACLE ClinicalTrials.gov number, NCT04585750.).

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Key Points

Abstract

Cite This Study